Focus: Palatin Technologies is a public biotech company focused on small-molecule therapeutics across multiple therapeutic areas including ophthalmology, cardiovascular, respiratory, nephrology, and immunology. The company operates at a pre-revenue to minimal-revenue stage with a public listing (PTN) but negligible commercial traction.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Palatin Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Palatin Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Palatin Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo